Acute pharmacological inhibition of acid-sensing ion channel 1a (ASIC1a) is efficacious in rodent models in alleviating symptoms of neurological diseases such as stroke and multiple sclerosis. Thus, ASIC1a is a promising therapeutic target and selective ligands that modulate it are invaluable research tools and potential therapeutic leads. Spider venoms have provided an abundance of voltage-gated ion channel modulators, however, only one ASIC modulator (PcTx1) has so far been isolated from this source. Here we report the discovery, characterization, and chemical stability of a second spider venom peptide that potently modulates ASIC1a and ASIC1b, and investigate the molecular basis for its subtype selectivity. p-TRTX-Hm3a (Hm3a) is a 37-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom with five amino acid substitutions compared to PcTx1, and is also three residues shorter at the C-terminus. Hm3a pH-dependently inhibited ASIC1a with an IC 50 of 1e2 nM and potentiated ASIC1b with an EC 50 of 46.5 nM, similar to PcTx1. Using ASIC1a to ASIC1b point mutants in rat ASIC1a revealed that Glu177 and Arg175 in the palm region opposite a-helix 5 play an important role in the Hm3a-ASIC1 interaction and contribute to the subtype-dependent effects of the peptide. Despite its high sequence similarity with PcTx1, Hm3a showed higher levels of stability over 48 h. Overall, Hm3a represents a potent, highly stable tool for the study of ASICs and will be particularly useful when stability in biological fluids is required, for example in long term in vitro cell-based assays and in vivo experiments.
Introduction
Over the last two decades, the growing knowledge on the molecular basis of various channelopathies and neurological disorders has fuelled an intense interest in the discovery and development of ion channel modulators as therapeutics and pharmacological tools (Bagal et al., 2013) . Spiders, in particular, have proved to be a rich source of such modulators. Their venoms contain numerous biologically active peptides that potently target a variety of ion channels (Klint et al., 2012; Saez et al., 2010) . As such, peptides isolated from spider venoms have been widely used to dissect the molecular mechanisms of channel function and their role in biological processes (Nebe et al., 1999; Osteen et al., 2016; Siemens et al., 2006) . In this respect, the acid-sensing ion channels (ASICs) are no different with a spider venom peptide being the first, and still the most potent, selective modulator known for ASICs.
ASICs are chordate-specific members of the degenerin/epithelial sodium channel family that are widely distributed in the nervous system and many non-neuronal cells (Boscardin et al., 2016) . They are primary mammalian acid sensors and as such are activated by protonation (Waldmann et al., 1997) . Six ASIC subtypes are known (ASIC1a/b, ASIC2a/b, ASIC3 and ASIC4), which can assemble as functional homotrimeric (ASIC1a/b, ASIC2a and ASIC3 only) or heterotrimeric channels (Hesselager et al., 2004; Jasti et al., 2007) . Each subunit consists of a large extracellular domain, two transmembrane helices, and short intracellular N-and C-termini. The combination of subunits in each channel affects the pH sensitivity, pharmacology, and kinetics of activation and desensitization (Hesselager et al., 2004) . ASIC1a is the most abundant ASIC subunit in the mammalian central nervous system. Unlike other ASICs, ASIC1a is also permeable to Ca 2þ , a property that has been associated with ASIC1a's role in acidosis-induced neuronal injury (Xiong et al., 2004; Yermolaieva et al., 2004) . ASICs have been implicated in a variety of pathophysiological conditions such as inflammatory and neuropathic pain (Bohlen et al., 2011; Deval et al., 2008; Duan et al., 2007) , psychiatric illness (Coryell et al., 2009) , multiple sclerosis (Vergo et al., 2011) , epileptic seizure termination (Ziemann et al., 2008) and ischemic stroke (McCarthy et al., 2015; Xiong et al., 2004) , hence are considered promising therapeutic targets (Wemmie et al., 2013) .
Although several small molecules have been demonstrated to modulate ASIC activity, they lack subtype specificity and potency, and are limited in their usefulness as pharmacological tools. In contrast, venom peptides are often extremely potent and can have very high selectivity for neuronal targets (Klint et al., 2012) . To date, six ligands targeting various ASIC subtypes have been isolated from animal venoms (Baron and Lingueglia, 2015) , The prototypical and therefore most studied ASIC ligand is the spider venom peptide, PcTx1, from the spider Psalmopoeus cambridgei (Escoubas et al., 2000) . PcTx1 inhibits homomeric ASIC1a with an IC 50 of~0.9 nM, and stabilizes the open state of ASIC1b. More recently it has been shown to also inhibit heteromeric ASIC1a/2b and ASIC1a/2a channels (Joeres et al., 2016; Sherwood et al., 2011) . The only other inhibitory peptide ligands of ASIC1 include the mambalgins, from the Mamba snakes (Dendroaspis spp.), which have been shown to inhibit ASIC1a and ASIC1b containing channels with IC 50 values between 11 and 300 nM (Baron and Lingueglia, 2015; Diochot et al., 2012) .
In a functional screening of a panel of spider venoms, we observed ASIC1a inhibitory activity from the venom of the Togo starburst tarantula (Heteroscodra maculata). Here, we describe the isolation, recombinant expression and characterization of a second potent inhibitor of ASIC1a. The peptide named p-theraphotoxinHm3a (hereafter Hm3a), was pharmacologically characterized to determine its ASIC subtype-selectivity, binding site, mechanism of action and stability.
Materials and methods

Venom peptide purification and characterization
Heteroscodra maculata venom was purchased from Spider Pharm (Yarnell, AZ, USA). The lyophilized venom was dissolved in water (1:10 dilution from original venom volume) and stored at À20 C until required. A total of 50 mL of the diluted venom was fractionated using RP-HPLC on a C18 column (Phenomenex Kinetex, 250 Â 4.6 mm, 100 Å) using a gradient of solvent A (0.05% trifluoroacetic acid (TFA) in H 2 O) and solvent B (90% acetonitrile, 0.043% TFA in H 2 O) as follows: 5% solvent B for 5 min, 5e20% solvent B for 10 min, 20e50% solvent B for 30 min, 50e80% solvent for 5 min, at a flow rate of 1 ml/min. Fractions were collected by monitoring eluent absorption at 214 and 280 nm and lyophilized. The dried fractions were dissolved in water and aliquots of each fraction were assayed for activity against rASIC1a expressed in Xenopus oocytes. A second RP-HPLC purification was carried out on the active fraction using a C18 column (Thermo Aquasil, 50 Â 2.1 mm, 190 Å) and a gradient of 10e30% solvent B over 20 min at a flow rate of 0.3 ml/min. All solvents used were HPLC grade.
RP-HPLC and MALDI-TOF mass spectrometry
Both analytical and semi-preparative RP-HPLC was performed using a Shimadzu Prominence HPLC system with the column at room temperature (21e22 C). Peptide mass was determined using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS using a Model 4700 Proteomics Analyzer (Applied Biosystems, Foster City, CA, USA) collected in both positive reflector and linear mode. All masses reported are monoisotopic MþH þ .
Fractions were mixed (1:1, v/v) with a-cyano-4-hydroxycinnamic acid matrix (7 mg/ml in 50% acetonitrile in H 2 O). To obtain a sequence tag of the peptide the reductive matrix 1,5-diaminonaphthalene (1,5-DAN) was used (Fukuyama et al., 2006) . The active fractions were mixed (1:1, v/v) with 1,5-DAN (10 mg/ml in 50% acetonitrile, 0.1% formic acid in H 2 O).
Peptide sequencing
The pure native peptide was reduced with 2-mercaptoethanol and alkylated by 4-vinyl-pyridinethen then sequenced via N-terminal Edman degradation (477A, Applied Biosystems, Foster City, CA, USA). Sequence homologies were determined using sequences obtained from a search of non-redundant protein databases via the BLAST server. Sequence alignments and percentages of similarity were calculated using BLASTP (Altschul et al., 1997) .
Production of recombinant Hm3a
Recombinant Hm3a was produced using the bacterial periplasmic expression system as described for PcTx1 (Klint et al., 2013; Saez et al., 2011) . The synthetic gene encoding PcTx1_D3C was cloned into the pLicC-MBP expression vector, then mutated using standard PCR protocols to produce a vector encoding Hm3a (Qi and Scholthof, 2008) . The fusion protein was expressed in E. coli BL21 (lDE3) and grown in Lysogeny broth medium to an OD 600 of 0.8e1.0. The culture was then cooled to 16 C and induced with 0.5 mM IPTG for 16 h. Cells were pelleted by centrifugation at 5000g then lysed via mechanical lysis at 28 kPa. The fusion protein was purified from the cell lysate via affinity chromatography using Ni-NTA Superflow resin (QIAGEN, Valencia, CA, USA). The peptide was cleaved from the fusion protein using TEV protease and purified by RP-HPLC on a C4 semi-preparative column (Phenomenex Jupiter, 250 Â 10 mm, 300 Å). Peptide purity was verified using analytical RP-HPLC on a C18 column (Thermo Aquasil, 50 Â 2.1 mm, 190 Å) and gradient of 10e50% solvent B over 40 min, at a flow rate of 0.25 ml/min. Masses of the eluted peptides were obtained using MALDI-TOF MS. The HPLC k' value [(peptide retention time e solvent retention time)/solvent retention time] for recombinant Hm3a was 23.5.
Electrophysiology
Peptide activity was assessed using two-electrode voltageclamp (TEVC) electrophysiology on Xenopus laevis oocytes. Oocytes preparation, cDNA/cRNA preparation and injections were performed as described . Stage VeVI oocyte were injected with 20e40 ng of ion channel cDNA/cRNA (Nanoject, 2000; WPI, Sarasota, FL, USA). Currents were recorded 1e6 days after injection under voltage-clamp using two standard glass microelectrodes of 0.5e2 MU resistance when filled with 3 M KCl solution. Oocytes were clamped at À60 mV (OC-725C oocyte clamp; Warner Instruments, Hamden, CT, USA). Currents were elicited by a drop in pH from 7.45 to 6.0 or 5.0 using a microperfusion system to allow rapid solution exchange (~1.5 ml/min) at room temperature. Conditioning pH of 7.45 was used for all experiments excluding mechanism of action studies at rASIC1a (activation and steady-state desensitization data), and rASIC1a_F350A mutant data performed using a conditioning pH of 7.35. HEPES was replaced by MES in buffers with pH below 6.8. A series of control currents were taken to account for the tachyphylaxis effect of ASICs in response to repeated pH stimulation prior to peptide application. Data were acquired (2000 Hz and filtered at 0.01 Hz) and analysis performed using pCLAMP software Version 10 (Axon Instruments, Sunnyvale, CA, USA). Peptides were prepared by serial dilutions in ND96 (96 mM NaCl, 1.8 mM CaCl 2 , 2 mM KCl, 2 mM MgCl 2 , 5 mM HEPES) solution supplemented with 0.1% bovine serum albumin (BSA, fatty-acid free) to minimize adsorption to plastic surfaces.
Stability assays
Thermal stability was assessed by dissolving Hm3a, PcTx1 or oxytocin in 10 mM phosphate-buffered saline pH 7.4 to a final concentration of 25 mM. Samples were incubated at 55 C and triplicate samples were taken at t ¼ 0, 4, 8, 24, and 48, quenched with 5% TFA solution, centrifuged at 17 000 g for 25 min and analyzed using RP-HPLC. The peak corresponding to intact peptide was identified by comparison to an untreated sample. Levels of peptide were quantified by integration of the peak area recorded at 214 nm, and plotted as a percentage of the peak area at t ¼ 0 for each respective sample.
Serum stability was performed using male AB human serum (Sigma-Aldrich). Serum was pre-warmed to 37 C for 15 min and added to lyophilized Hm3a, PcTx1, or oxytocin to a final concentration of 50 mM. Triplicate samples were taken at t ¼ 0, 1, 2, 4, 8, 12, 24 , and 48 h for Hm3a and oxytocin, and t ¼ 0, 2, 4, 24, and 48 h for PcTx1, quenched with 20% TFA solution, and stored at 4 C for 15 min to precipitate serum proteins. Samples were centrifuged at 17 000 g for 25 min and analyzed using RP-HPLC. The peak corresponding to intact peptide was identified by comparison to an untreated sample and levels of peptide were quantified as described above.
Deposition of protein sequence information
Peptide sequence information derived for Hm3a has been submitted to the publicly accessible UniprotKB database (http://www. uniprot.org/) and has the accession number C0HKD0.
Materials
Chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA, via Sigma Australia, Castle Hill, NSW, Australia), with the ex-
Alexandria, NSW, Australia) and TFA (Auspep Tullamarine, VIC, Australia). Recombinant TEV protease was produced in-house using a previously described protocol (Fang et al., 2007) .
Animal welfare and ethics statement
Oocyte studies complied with the Australian code of practice for care and use of animals for scientific purposes, 8th Ed. 2013. The protocol was approved by The University of Queensland Animal Ethics Committee (Approval No. QBI/059/13/ARC/NHMRC). Xenopus laevis oocytes were obtained via recovery surgery performed under tricaine methanesulfonate anaesthesia (animals bathed in 1.3 mg/ ml). All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny et al., 2011; McGrath et al., 2010) .
Data analysis and statistical procedures
Data were analyzed with the software Graphpad Prism 6 (La Jolla, CA, USA). The half-maximal response (IC 50 , EC 50 or pH 50 ) and Hill coefficient (slope) were obtained through a non-linear fit to the data of a four parameter logistic equation ("sigmoidal doseresponse"). Half-life (t 1/2 ) was obtained through a non-linear fit to the data of a "dissociation e one phase exponential decay" equation. Results are reported, in the text or on the figures, as means ± SEM. They represent the mean of n individual measurements on different oocytes. Statistical analysis and comparison between two groups was performed using Student's t-test with Welch's correction where standard deviations were not assumed to be equal. Comparisons of three or more groups were performed with one-way ANOVA and Tukey's Test for IC 50 comparisons, and a two-way ANOVA and Tukey's Test for stability assays.
Results and discussion
Despite sustained interest in ASIC1 as a promising drug target (Wemmie et al., 2013) , the current array of ASIC1 modulatory ligands available as selective pharmacological tools and therapeutic leads is extremely limited. The difficulty in developing more selective small molecule ASIC inhibitors as therapeutic leads is illustrated by a series of medicinal chemistry studies by the Merck Research Laboratories. Three studies using different scaffolds all resulted in more potent molecules against ASICs, however, all had significant off-target effects resulting in substantial sedation in animal studies (Kuduk et al., 2009a (Kuduk et al., , 2010 (Kuduk et al., , 2009b . Based on the discovery of PcTx1 in a spider venom (Escoubas et al., 2000) as well as preliminary screening data from past studies (Escoubas, unpublished) we hypothesized that spider venoms, and especially tarantula venoms, should be a valuable source of additional novel ASIC modulators. Discovery of novel ligands, and understanding the molecular basis for differences in their biological properties (such as structural and chemical stability) and functions provides valuable insight to develop improved ligands.
Identification and purification of Hm3a
Screening a panel of spider venoms on rat ASIC1a expressed in Xenopus laevis oocytes revealed that Heteroscodra maculata (1/ 1000-fold dilution) venom robustly (>90%) inhibits this channel. Assay-guided fractionation led to the identification of a minor, early-eluting peptide (Fraction 12) responsible for the rASIC1a inhibitory activity (Fig. 1A) . The peptide has an observed monoisotopic MþH þ of 4285.05 ( Fig. 1B) and was named p-TRTX-Hm3a, hereafter Hm3a, according to a rational nomenclature system for naming peptides from animal venoms (King et al., 2008) .
The full-length amino acid sequence of Hm3a was determined using Edman degradation and verified using mass spectrometry. The theoretical oxidized monoisotopic m/z (MþH þ ¼ 4285.03) of the Hm3a sequence matched the observed monoisotopic mass, suggesting the presence of a free carboxylic acid at the C-terminus and three disulfide bonds. The Hm3a sequence matched that of another ASIC-inhibiting peptide previously isolated from this venom from an HPLC fraction of similar retention time and named Hm12 (Escoubas, unpublished). Hm3a shares 82% identity with PcTx1, the prototypical ASIC1a inhibitor from Psalmopoeus cambridgei venom (Fig. 1C) . Hm3a differs from PcTx1 by five point mutations and a three-residue Cterminal truncation. Native Hm3a is highly potent on rASIC1a, inhibiting acid-evoked currents with an IC 50 of 2.6 ± 1.3 nM when applied at pH 7.45 (Figs. 1D and S1A). Due to the high sequence identity, conserved cysteine framework, and similar pharmacology between Hm3a and the inhibitor cysteine knot (ICK) fold peptide PcTx1 (PDB: 2KNI), it is highly likely that Hm3a also conforms to the ICK fold (Fig. 1E) .
Recombinant production of Hm3a
In order to obtain sufficient material to carry out further pharmacological characterization of Hm3a, we used an E. coli recombinant expression system that we have previously employed to produce many disulfide rich venom peptides including PcTx1 (Klint et al., 2013; Saez et al., 2011) . Following IPTG induction, the Hm3a-fusion protein was the dominant cellular protein present ( Fig. 2A) yielding~1 mg of correctly folded peptide per liter of bacterial culture at >95% purity (determined using RP-HPLC and MS) (Fig. 2B ). The observed M þ H þ (4372.58) was in accordance with the calculated value (4372.06) for Hm3a with an additional Nterminal serine left over from the TEV recognition site (Fig. 2B  inset) . The recombinant variant was subsequently used for all further characterization studies.
Effects of Hm3a on ASICs
Recombinant Hm3a was similarly potent to the native peptide with an IC 50 of 1.3 ± 0.2 nM (Fig. 3A) confirming that the determined sequence is responsible for the observed ASIC1a activity. Furthermore, it shows that the addition of an extra residue on the N-terminus (the serine from the TEV cleavage site) has little effect on the inhibitory activity of the peptide, consistent with the welltolerated addition of a serine or tyrosine to the N-terminus of PcTx1 (Saez et al., 2011; Salinas et al., 2006) . Having ascertained the functional integrity of the recombinant Hm3a, the remaining characterization studies were performed using the recombinant peptide. The potency and selectivity of Hm3a was assessed using TEVC electrophysiology at a conditioning pH of 7.45 on oocytes expressing homomeric rASIC1a, rASIC1b, rASIC2a, rASIC3, human ASIC1a, hASIC1b, and co-expressed rASIC1a/ASIC1b (a potential mixture of homo-and heteromeric channels) (Fig. 3 ). Hm3a is highly selective for ASIC1, with no observable effect on rASIC2a or rASIC3 up to 10 mM (Fig. 3A) . In stark contrast, Hm3a strongly potentiated rASIC1b (~4-fold increase in current amplitude) with an EC 50 of 46.5 ± 6.2 nM (Fig. 3B) , as has previously been reported for PcTx1 (Chen et al., 2006) . The potentiating effect was also observed on heteromeric rASIC1a/ASIC1b channels with higher potency (EC 50 of 17.4 ± 0.5 nM), but lower efficacy (less than 2-fold increase in current amplitude) as compared to homomeric rASIC1b (Fig. 3B) .
We next assessed species-dependent effects of Hm3a on ASIC1. Similar to the rat isoforms, Hm3a also inhibited hASIC1a (IC 50 of 39.7 ± 1.1 nM) and potentiated hASIC1b (EC 50 of 178.1 ± 1.3 nM); it was however~30-fold, and~3.8-fold less potent, respectively, than on the rat isoforms (Fig. 3C) . The Hill coefficients from the concentration-effect curves of Hm3a on both rat and human ASIC1a and ASIC1b were 1.3e1.6, suggesting positively cooperative binding of more than one Hm3a peptide per ASIC1 trimer. This is consistent with the co-crystal structures of cASIC1 and PcTx1 that showed up to three PcTx1 peptides bound per channel (see Fig. 5A ) (Baconguis and Gouaux, 2012; Dawson et al., 2012) .
In the study by Chen et al. (Chen et al., 2006) that first demonstrated the potentiation of ASIC1b by PcTx1, the authors were unable to determine an accurate EC 50 as a plateau in the PcTx1-induced potentiation effect was not reached. Here, we were able to show a maximal response for Hm3a potentiation of both rat and human ASIC1b allowing more robust comparison of EC 50 values. PcTx1 has been shown to inhibit both ASIC1a homomers (Escoubas et al., 2000) as well as rASIC1a/ASIC2b and rASIC1a/ ASIC2a heteromers (Joeres et al., 2016; Sherwood et al., 2011) , however, no activity has been reported on channels resulting from rASIC1a/ASIC1b co-expression (presumably containing heteromers). Our results indicate that rASIC1a/ASIC1b heteromers are sensitive to Hm3a in the mid-nanomolar range. A better understanding of the interaction of these peptides with both ASIC1b and ASIC1a/1b heteromers is crucial when they are used as ASIC1a inhibitors in animal studies because both ASIC1a and ASIC1b are highly expressed in the peripheral nervous system in rodents (Wu et al., 2004) . The use of high concentrations of Hm3a or PcTx1 may lead to confounding results, and possible undesirable side-effects, because inhibition of ASIC1b has caused analgesic effects in inflammatory and nociceptive pain models in ASIC1a-knockout mice (Diochot et al., 2012) .
Despite the high sequence identity of Hm3a to PcTx1, Hm3a is slightly less potent on rASIC1a (~3-fold compared to PcTx1 in our previous studies) (Saez et al., 2011 (Saez et al., , 2015 (Figs. 1D and 3A) . From our previous structure-activity studies on PcTx1, we have shown that truncation of the three C-terminal residues (Pro38, Lys39, Thr40; variant named D3C) resulted in a~4-fold decrease in activity (Saez et al., 2015) . Furthermore, a P38A mutation of PcTx1 was alsõ 4-fold less potent than wild-type PcTx1, leading us to the conclusion that the channel interaction mediated by Pro38 in PcTx1 could account for the slight loss in activity observed in D3C (Saez et al., 2015) . Being equivalent in length to the PcTx1_D3C variant, Hm3a also lacks a proline at position 38. Hence, we hypothesized that the potency of Hm3a on rASIC1a could be enhanced by the addition of a proline at the C-terminus (Hm3a_P38). Hm3a_P38 had an IC 50 of 0.4 ± 0.1 nM (Fig. 3D) or a 3.3-fold increase in potency as compared to wild-type recombinant Hm3a, in complete agreement with our prediction.
Extensive mutagenesis of PcTx1 (Saez et al., 2011 (Saez et al., , 2015 , along with two co-crystal structures in complex with chicken ASIC1 (Baconguis and Gouaux, 2012; Dawson et al., 2012) have been instrumental in defining the PcTx1 pharmacophore. Three of the residue differences between PcTx1 and Hm3a (D2P, G9S, and E19A) were not identified as potential contacts in structural studies. As a result, the effect of these mutations in PcTx1 have not been studied, and here we show that these mutations do not appear to be crucial for activity against rASIC1a. Thr37 of PcTx1 was identified as a crystal contact, however a PcTx1_T37A mutant was shown to be equipotent with wild-type PcTx1 (Saez et al., 2015) , in good agreement with the Hm3a potency at rASIC1a (Thr37 is a valine in Hm3a). The only residue difference between Hm3a and PcTx1 that falls within the key pharmacophore residues is R28K. Arg28 in PcTx1 makes multiple channel contacts and the PcTx1_R28A mutant had 14.5-fold lower activity on rASIC1a (Saez et al., 2015) . In the case of Hm3a, the conservative mutation of arginine to lysine at position 28 appears to have little to no deleterious effect on peptide activity, thus the substitution is both functionally and structurally neutral. Although lysine has one less amino group, full retention of activity suggests that not all the interactions proposed in crystal studies are making energetically important contributions.
Mechanism of action of Hm3a on ASIC1
The homologous peptide PcTx1 mimics the binding of protons in the acidic pocket of ASIC1a, and inhibits channel currents by shifting the pH of half-maximal effect (pH 50 ) of steady-state desensitization (SSD) and activation to more alkaline values, pushing channels into a desensitized (non-conducting) state at pH 7.45 (Chen et al., 2005) . Thus we assessed the effects of 30 nM Hm3a on SSD of rASIC1a (Fig. 4A) . Application of Hm3a in the conditioning solution induced a parallel alkaline shift in the pH 50 SSD of rASIC1a by~0.37 pH units from 7.24 ± 0.02 to 7.61 ± 0.02 (Fig. 4C ). This shift in SSD by Hm3a pushes ASIC1a into a desenzitised state at pH 7.45 (i.e. inhibition), however at 30 nM the magnitude of the shift is insufficient to induce inhibition when applied at conditioning pH 7.9. Therefore at pH 7.9, the channels are in the resting state but in the presence of Hm3a. This allows us to study the effect of the peptide on the pH-dependence of channel activation, without the peptide inducing channel inhibition (Fig. 4B) . The pH 50 of activation (pH 50 ACT ) of rASIC1a under control conditions was 6.08 ± 0.04, as compared to 6.28 ± 0.06 when conditioned with 30 nM Hm3a (Fig. 4C) . Thus Hm3a lowered the proton concentrations required for activation by~0.20 pH units.
The alkaline shift caused by Hm3a in the pH of both SSD and activation confirms the analogous mechanism of inhibition to PcTx1.
The on-rate of Hm3a on rASIC1a was examined by application of 30 nM peptide at pH 7.45 for increasing periods of time followed by activation at pH 6. Fitting a single exponential function to the time course of inhibition data revealed a time to 50% inhibition (t 1/2 ) of ~16 s, with maximal inhibition reached after~90 s (Fig. 4D) . The slow onset of Hm3a inhibition may not be reflective of the actual binding on-rate for the peptide-channel interaction. Hm3a causes inhibition via inducing SSD of ASIC1a, which in itself is a slowly induced process (plateauing at >100 s for pH 7.05 exposure) (Babini et al., 2002) , and likely takes longer than the actual on rate of Hm3a. In agreement with this, application of 30 nM Hm3a for less than 10 s led to potentiation of currents (Fig. S3) , indicative of a rapid interaction between ASIC1a and Hm3a, similar to previously reported observations with PcTx1 on rASIC1a (Chen et al., 2005) . The on rate of Hm3a was similar to PcTx1 as previously reported using oocyte electrophysiology. Full inhibition of rASIC1a induced by 30 nM PcTx1 was achieved~150 s after peptide application, with a time constant (Tau) of 52 s (Chen et al., 2006) . Recovery of rASIC1a current after inhibition induced by a 180 s exposure to 30 nM Hm3a at pH 7.45 was complete after~360 s of peptide washout, with a t 1/2 of~132 s (Fig. 4E ). ASIC1a recovers from the desensitized state over a time course of several seconds (time constant~10 s) (Babini et al., 2002) , hence the slower recovery from Hm3a inhibition can be largely attributed to unbinding of the peptide from the channel rather than simply recovery from SSD. Taken together, the mechanism and kinetics data shows that the homologous peptides Hm3a and PcTx1 have an almost identical effect on ASIC1a. In order to determine the mechanism of ASIC1b potentiation by Hm3a, we analyzed the decay time constants of whole cell current desensitization. Control ASIC1b currents elicited by a pH drop to 5.0 decayed with a time constant (t) of 1.28 ± 0.06 s (Fig. 4F ). Hm3a caused a concentration-dependent increase in the time constant of desensitization, and could be fit with the Hill function to yield an EC 50 of 35.9 ± 17.2 nM, which is consistent with the EC 50 determined for potentiation of peak current. Thus, Hm3a increases the time taken for channel desensitization, resulting in a prolonged open state that is observed as an increase in current amplitude consistent with the effect of PcTx1 on ASIC1b (Chen et al., 2006) .
Characterizing the molecular interactions involved in subtype and species selectivity of Hm3a on ASIC1
The binding site of PcTx1 on ASIC1a was first studied using a chimeric channel approach (Chen et al., 2006; Salinas et al., 2006) and has since been extensively defined (Baconguis and Gouaux, 2012; Dawson et al., 2012; Saez et al., 2011 Saez et al., , 2015 . PcTx1 binds primarily to a-helix 5 at the bottom of the acidic pocket and a short stretch of residues following b-sheet 3 in the palm of the adjacent subunit ( Fig. 5A and B) . The rASIC1a residue Phe350 (Phe352 in hASIC1a) on a-helix 5 in the thumb domain is particularly important for interaction with the peptide. Previous studies using diluted Psalmopoeus cambridgei venom (containing PcTx1) or recombinant PcTx1 on the hASIC1a_F352L or rASIC1a_F350A mutants, respectively, showed a total lack of inhibition (Saez et al., 2015; ). However, shortly after, Sherwood et al., showed evidence that PcTx1 could still bind to the mutant channel (i.e., preincubation with 200 nM PcTx1 prevented the potentiating activity of big dynorphin) . Given the similarity of Hm3a with PcTx1 in sequence and pharmacology we assume it will share the same binding site.
In order to confirm this, Hm3a was tested on the rASIC1a_F350A mutant. Our studies with higher concentrations (up to 10 mM) show that not only can Hm3a still bind, but also that it has an interesting dual functional effect (Fig. 5C ). Initial studies using a conditioning pH of 7.45 (to match that of all other concentration-effect data presented) showed that Hm3a strongly potentiated currents at Fig. 3 . Concentration-effect curves of recombinant Hm3a for (A) homomeric rASIC1a, rASIC2a, and rASIC3 (n ¼ 6e10), (B) homomeric rASIC1b and heteromeric rASIC1a/ASIC1b channels (heteromeric rASIC1a/ASIC1b is the response observed in oocytes co-injected with both rASIC1a and rASIC1b cRNA) (n ¼ 6), and (C) homomeric hASIC1a and hASIC1b (n ¼ 7). (D) Concentration-effect curves of Hm3a_WT and Hm3a_P38 mutant on homomeric rASIC1a (n ¼ 4e10). *Statistical comparison of logEC 50 between rASIC1b and heteromeric rASIC1a/ASIC1b data sets (panel B); p ¼ 0.0052 and F ¼ 8.069, and logIC 50 for Hm3a WT and P38 mutant data sets (panel D); p ¼ 0.0029 and F ¼ 9.388. Conditioning pH used to generate all the above data was pH 7.45, and example traces are shown in Fig. S1 . Data are mean ± SEM.
concentrations over 300 nM. This effect was maximal at 3 mM (~2.8-fold increase in current amplitude), and a small decrease in the potentiation efficacy was seen at 10 mM. Given that Hm3a inhibits rASIC1a by inducing SSD and that the rASIC1a_F350A pH 50 of SSD is shifted by~0.1 units in the acidic direction compared to wild-type rASIC1a (Fig. S4) , the Hm3a concentration-effect curve was repeated using a conditioning pH of 7.35 (i.e., a conditioning pH that is~0.2 pH units above the pH 50 for SSD, thus equivalent to using pH 7.45 for wild-type rASIC1a). Under these conditions Hm3a, from 100 nM to 1 mM, once again potentiated currents (albeit with a much decreased efficacy), however at concentrations greater than 3 mM Hm3a induced channel inhibition. This suggests that despite losing the large number of contacts (five crystal contacts) made between Phe350 and PcTx1 (and by similarity, Hm3a) (Saez et al., 2015) there are still sufficient residual contacts to mediate a functional interaction at higher concentrations. It is thus tempting to speculate that during the potentiating effect (observed with lower peptide concentrations), Hm3a binds with partial occupancy and facilitates channel opening. Whereas, at higher concentrations the increased binding site occupancy (3 per channel) is sufficient to push channels into the desensitised state. Another possible explanation could be that in the presence of the F350A mutation, Hm3a adopts a different orientation when bound, resulting in the complex concentration-dependent functional outcome observed in our study. ASIC1b is highly expressed in peripheral sensory nerves and appears to play a key role in mediating acid-induced nociception, at least in rodents (Diochot et al., 2012; Hoagland et al., 2010) . Thus determining the molecular basis for Hm3a potentiation of ASIC1b is an important step to understand potential complications when interpreting in vivo data, and enabling the design of more selective ASIC1 modulators. Thus, we further characterized the potential interactions sites of Hm3a on ASIC1. ASIC1a and ASIC1b are splice isoforms that only differ in the first third of the protein (identical from residue 186 of rASIC1a onwards). The use of a series of chimeras between rASIC1a and rASIC1b revealed a small stretch of residues 167e185 of rASIC1a (19 residues N-terminal to the splicesite) that are sufficient to confer the difference in peptide activity between rASIC1a and rASIC1b (inhibition vs potentiation)(coloured magenta in Fig. 5B and sequence shown in Fig. 5D ) (Chen et al., 2006) . Interestingly, the only residue difference within the known PcTx1 binding site between human and rat ASIC1a, is Ala178 in the rat channel (valine in hASIC1a) is also part of this small sequence stretch. We examined this region in further detail with rASIC1a point mutants for all PcTx1:cASIC1 crystal contact residues, predicting that several of the non-conserved residues should be responsible for the different subtype selectivity and speciesspecific pharmacology of Hm3a and PcTx1 at ASIC1 (Fig. 5D and E) .
The IC 50 of Hm3a on rASIC1a_A178V (2.1 ± 0.7 nM) was only slightly increased compared to wild-type rASIC1a (Fig. 5E ), which does not account for the 30-fold difference in IC 50 on rat and human ASIC1a. We concluded that Ala178 is not strongly involved in channelepeptide interaction, in agreement with molecular dynamics predictions whereby the equivalent residue on cASIC1 (Gln179) does not form persistent interactions with PcTx1 (Saez et al., 2015) . Furthermore, this finding is consistent with a previous study in which the mechanism of action of PcTx1 (i.e., alkaline shift of SSD) was suggested to be responsible for the apparent lower Cyan ¼ residues identical in all subtypes, grey ¼ semi-conserved residues (i.e. identical to rASIC1a). Channel residues in rASIC1a that correspond to cASIC1 crystal contacts were mutated in this study, and the residue they were mutated to are bolded. (E) Concentration-effect curves for Hm3a at wild-type rASIC1a and point mutants (n ¼ 6e10). A statistically significant difference from rASIC1a WT in logIC 50 inhibition by Hm3a was present for both rASIC1a R175C and E177G mutants, p < 0.0001, represented by *. Data for panel E were performed using a conditioning pH of 7.45. Data are mean ± SEM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
potency of PcTx1 at hASIC1a compared to rodent ASIC1a, as the pH 50 SSD of hASIC1a is more acidic than that of the rat or mouse isoform (Sherwood and Askwith, 2008) . The IC 50 of Hm3a on rASIC1a_H173S (1.8 ± 1.0 nM), rASIC1a_F174Y (1.9 ± 0.9 nM), and rASIC1a_A178P (2.1 ± 1.0 nM) was less than 2-fold different compared to that on wild-type rASIC1a. Consequently, these three residues are not likely to be making important interactions with the peptides for functional activity. In contrast, there was a significant decrease in Hm3a activity on both rASIC1a_R175C and rASIC1a_E177G, with an IC 50 of 23.3 ± 1.1 nM and 13.2 ± 1.2 nM, respectively (Fig. 5E ). These mutations were made to make the rASIC1a-binding interface resemble that of rASIC1b. None of these mutations drastically affected the channels sensitivity to protons (in the form of pHdependence of SSD and activation) (Fig. S4) , thus, any loss in potency is likely due to a loss of important interactions made between the peptide and channel, rather than changes in channel function or peptide mechanism. Consistent with this result, PcTx1:ASIC1 crystal structures and molecular dynamics studies (Baconguis and Gouaux, 2012; Dawson et al., 2012; Saez et al., 2015) showed that Arg175 and Glu177 of rASIC1a (Arg176 and Glu178 in cASIC1) make contact with Trp24 and Arg27 of PcTx1, respectively, both major pharmacophore residues (Saez et al., 2011 (Saez et al., , 2015 . Although the interaction between PcTx1 and ASIC1a is well characterized, no study has so far demonstrated which individual residues determine subtype specificity between rASIC1a and rASIC1b. Here we show that Hm3a interacts with both ASIC1a and ASIC1b with a~35-fold difference in potency (but different functional outcomes) and identified Arg175 and Glu177 of rASIC1a as two of the causative residues which can account for the subtype specificity of Hm3a, and most likely PcTx1. This improved understanding of the binding interaction between peptide and channel should aid the design of more specific analogues of these peptides.
Stability of Hm3a and PcTx1
Given the likely role of ASIC1a in a range of pathological conditions, and the need to use selective pharmacological tools for target validation in vivo, it is important to understand the thermal and biological stability of peptides such as Hm3a and PcTx1. Despite its extensive use as a research tool in vivo, the stability of PcTx1 has never been reported. Therefore, we evaluated the stability of Hm3a and PcTx1 in comparison to the clinically used peptide oxytocin at 55 C in phosphate-buffered saline at pH 7.4, and in human serum (Fig. 6) . Hm3a proved to have high thermal stability with~10% loss after 48 h at 55 C. In comparison, PcTx1 showed slightly more breakdown with~24% loss after 48 h, and oxytocin showed a nearlinear breakdown over time with~38% of oxytocin remaining at 48 h. Similarly, Hm3a was largely unaffected in human serum with 87% intact peptide after 48 h. In contrast, degradation of PcTx1 and oxytocin continued over the assay time with~35% and~40% of peptide respectively remaining after 48 h.
It is often claimed that ICK peptides are highly stable and resistant to thermal, chemical and enzymatic degradation and this has been demonstrated for several spider venom peptides, u-Hv1a, ProTx-II, GsMTx-4, and GTx1-15 (Herzig and King, 2015; Kikuchi et al., 2015) . Interestingly, despite their high degree of sequence similarity, Hm3a was more stable than PcTx1 when challenged with either high temperature or human serum. The improved stability of Hm3a over PcTx1 may be due to Hm3a's fewer charged residues (particularly lysines at the C-terminus), which are common cleavage sites for proteolytic enzymes such as trypsin (Olsen et al., 2004) . We conclude that the substantially higher biological stability of Hm3a as compared to PcTx1 makes it a substantially more attractive tool for studying the role of ASICs in biological fluids and in in vivo studies. 
Off-target effects of Hm3a
Many spider venom peptides are gating modifiers of voltagegated ion channels. Due to high suitability of Hm3a for in vivo studies, Hm3a was also tested on therapeutically-relevant off-targets including the rat voltage-gated sodium channel subtype 1.2 (Na V 1.2) and the voltage-gated potassium channel subtypes 10.1 (K V 10.1) and 11.1 (K V 11.1, or hERG). Na V 1.2 is predominantly expressed in the central nervous system and prolonged opening of the channel is implicated in the onset of epileptic disorders (Sugawara et al., 2001) . K V 10.1 is implicated in a variety of cellular processes including cell proliferation and tumour progression (Ouadid-Ahidouch et al., 2016) whereas K V 11.1 is vital for cardiac function (Ouadid-Ahidouch et al., 2016) . At 10 mM, Hm3a had no effect on the voltage-dependence of activation of these channels (Fig. S5) , suggesting a substantial selectivity of Hm3a towards ASIC1 over other ASICs subtypes as well as several voltage-gated channels.
Conclusions
We have identified and characterized a new potent peptide modulator of ASIC1 from the venom of H. maculata, and suspect that tarantula or other spider venoms may harbour even more, potent and selective peptide inhibitors of ASICs. Despite the high sequence and pharmacological similarity of Hm3a and PcTx1, Hm3a appears to be superior in terms of biological stability. Furthermore, through rational engineering of Hm3a, we produced a more potent variant of the peptide making its ASIC1a inhibitory potency on par with PcTx1. We also identified several determinant residues in rASIC1a for ASIC1a/1b selectivity studies. Overall, this study will contribute to the rational engineering and development of ASIC modulators with improved subtype selectivity and facilitate the development of novel ASIC-targeting therapeutic leads and research tools.
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